GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 09:05:24 02/05/2024 pm IST 5-day change 1st Jan Change
1,728 GBX +1.38% Intraday chart for GSK plc +4.69% +19.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK : Buy rating from Deutsche Bank ZD
GSK : UBS keeps its Buy rating ZD
GSK : UBS reiterates its recommendation on the share CF
Moderna quarterly sales beat expectations but plummet from previous year RE
Deutsche Bank likes TP ICAP but says sell CMC AN
GSK : JP Morgan reaffirms its Sell rating ZD
GSK: JP MORGAN RAISES TARGET PRICE TO 1660P FROM 1530P… RE
Chimeric Therapeutics Appoints COO; Shares Rise 4% MT
Health Care Climbs as Pfizer, GSK Rise -- Health Care Roundup DJ
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits MT
FTSE 100 down ahead of US interest rate decision AN
London Stocks Retreat as UK Manufacturing Sector Reverts to Contraction MT
GSK PLC : Encouraging start to 2024; guidance raised Alphavalue
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
GSK : UBS gives a Buy rating ZD
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET DJ
Transcript : GSK plc, Q1 2024 Earnings Call, May 01, 2024
FTSE 100 treads water as Fed takes centre-stage AN
GSK Q1 Core Earnings, Revenue Advance; 2024 Outlook Lifted -- Shares Up Pre-Bell MT
GSK : Gets a Sell rating from JP Morgan ZD
GSK raises forecast, boosted by vaccines RE
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET DJ
European Midday Briefing : Fed Awaited With Likelihood Rates Held High For Longer DJ
Haleon backs guidance as profit edges up in first quarter AN
FTSE 100 shakes off New York slump before Fed AN
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.05 GBP
Average target price
20.2 GBP
Spread / Average Target
+18.45%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK, Vir Biotechnology Seek US FDA's Nod to Amend Emergency Use Authorization for COVID-19 Treatment